Publications by authors named "Marla B Sultan"

Claim this Profile
T
The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.
Martha Grogan, Margot K Davis, Maria G Crespo Leiro, Marla B Sultan, Balarama Gundapaneni

Future Cardiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy.
Ronald Witteles, John L Jefferies, Suraj Kapa, Francesco Cappelli, Marla B Sultan

JACC CardioOncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT.
Brett W Sperry, Marla B Sultan, Balarama Gundapaneni, Sandi See Tai, Ronald M Witteles

JACC CardioOncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Martha Grogan, Margot K Davis, Maria G Crespo-Leiro, Marla B Sultan, Balarama Gundapaneni

Eur J Heart Fail· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
Pablo Garcia-Pavia, Marla B Sultan, Balarama Gundapaneni, Yoshiki Sekijima, Federico Perfetto

JACC Heart Fail· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sanjiv J Shah, Nowell Fine, Pablo Garcia-Pavia, Allan L Klein, Fabio Fernandes, Marla B Sultan

JAMA Cardiol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Perry Elliott, Balarama Gundapaneni, Marla B Sultan, Monica Ines, Pablo Garcia-Pavia

Eur J Heart Fail· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Marla B Sultan

Future Cardiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A natural history analysis of asymptomatic gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Teresa Coelho, Isabel Conceição, Márcia Waddington-Cruz, Denis Keohane, Marla B Sultan

Amyloid· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
Mazen Hanna, Nowell M Fine, Balarama Gundapaneni, Marla B Sultan, Ronald M Witteles

JACC Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Huihua Li, Mark Rozenbaum, Michelle Casey, Marla B Sultan

Cardiology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Perry Elliott, Balarama Gundapaneni, Marla B Sultan

Circ Heart Fail· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Mazen Hanna, Thibaud Damy, Martha Grogan, Michelle Stewart, Balarama Gundapaneni, Marla B Sultan

Future Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary.
Jose Nativi-Nicolau, Daniel P Judge, James E Hoffman, Balarama Gundapaneni, Denis Keohane, Marla B Sultan

Future Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Marla B Sultan

Circ Heart Fail· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.
Arianna Burton, Adam Castaño, Marianna Bruno, Steve Riley, Jennifer Schumacher, Marla B Sultan

Drug Des Devel Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
Jose Nativi-Nicolau, Daniel P Judge, James E Hoffman, Balarama Gundapaneni, Denis Keohane, Marla B Sultan

ESC Heart Fail· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
Thibaud Damy, Marla B Sultan, Ronald Witteles

Eur J Heart Fail· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Alan B Miller, James L Januzzi, Blair J O'Neill, Balarama Gundapaneni, Terrell A Patterson, Marla B Sultan

Am J Cardiol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy.
Claudio Rapezzi, Marla B Sultan, Mathew S Maurer

JACC Heart Fail· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Thibaud Damy, Pablo Garcia-Pavia, Mazen Hanna, Daniel P Judge, Giampaolo Merlini, Marla B Sultan

Eur J Heart Fail· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Mazen Hanna, Thibaud Damy, Martha Grogan, Michelle Stewart, Balarama Gundapaneni, Marla B Sultan

Am J Cardiol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Claudio Rapezzi, Perry Elliott, Thibaud Damy, Jose Nativi-Nicolau, John L Berk, Marla B Sultan

JACC Heart Fail· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
Peter A Lockwood, Vu H Le, Melissa T O'Gorman, Terrell A Patterson, Marla B Sultan

Clin Pharmacol Drug Dev· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
Peter Huber, Alison Flynn, Marla B Sultan, Huihua Li, Denise Rill

Amyloid· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis